Study Phase 3

A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate

Trial Information

Generic NameMethylphenidate HClProduct NameCONCERTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment357% Female47.3%% White82%
Product ClassStimulants/ADHD/AnorexiantsSponsor Protocol NumberCR015058 (CONCERTA-ATT-3014 )Data PartnerJohnson & JohnsonCondition StudiedAttention Deficit Hyperactivity DisorderMean/Median Age (Years)35.8

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.